Explore every episode of the podcast Simply Oncology
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Episode 125: FOXTROT & Discussing peri-operative treatment in colon cancer with Professor Jenny Seligmann | 21 Oct 2026 | 00:28:35 | |
Join us today for an amazing round up of the peri-operative space in colon cancer with the excellent Professor Jenny Seligmann from Leeds. We discuss all aspects of the FOXTROT trials and where this peri-operative space. With the AZURE trial reporting this weekend at ESMO we discuss the landscape in peri-operative management. | |||
| Episode 124: Real World Evidence lessons in Kidney Cancer with Professor Daniel Heng | 16 Oct 2026 | 00:24:06 | |
🎙️Join us as we finish our discussion through Kidney Cancer with the wonderful Professor Daniel Heng of Calgary,Canada🇨🇦 🎙️In this episode we focus on the Real World Evidence 🌎🔎 from the IMDC 🎙️what cane we learn from comparing complete response rates and durable responses between IO-IO therapy and IO-VEGF therapy🤔 🎙️What has Danny learned through setting up the IMDC and how to bring people with you? 🎙️What areas does Danny think need expanding in the future in Renal Cancer? All this and more alongside some genuine laughter 😂with Danny Enjoy!!! | |||
| Episode 123: The Big IMDC Kidney Cancer episode with Professor Daniel Heng | 09 Oct 2026 | 00:26:09 | |
🚨Join us today as we discuss all things kidney cancer !! 🎙️We hear how Danny Heng started the IMDC (International Metastatic renal cell carcinoma Database Consortium) prognostic score in advanced kidney cancer. 🎙️We discuss how the IMDC moved as prognostic score to then being part of stratification for modern metastatic kidney cancer trials. 🎙️IMDC now shapes what drugs we give for 1st line metastatic kidney cancer. 🙌🏽Kidney cancer survivals have quadrupled since the early Interferon era 💡We discuss biomarkers 🧭 💡We discuss more biomarkers - KIM 1, Clusters, Composite Biomarkers.
☀️ Enjoy ☀️ | |||
| Episode 122: In the Clinic - Scoping Acute Oncology services in the future with Dr Caroline Wilson | 02 Oct 2026 | 00:26:35 | |
Join us as we complete our discussion on all things Acute Oncology Services with the superb Dr Caroline Wilson PhD FRCP from the The Christie NHS Foundation Trust. | |||
| Episode 121: In the Clinic - The Acute Oncology Service - Cancer's Front Door Heroes with Dr Caroline Wilson | 25 Sep 2026 | 00:27:39 | |
Welcome back - today we are discussing Acute Oncology Services and how they have evolved over the last 15 years. Why were they set up ? To give cancer patients support and care when they need it most - when they are admitted to hospital with problems. Do you know your type 1 from your type 2 or 3 Acute oncology patient? We talk all things AOS with the wonderful Dr Caroline Wilson from The Christie Hospital in Manchester. What would your ideal Acute Oncology Service look like? Caroline tells us how she is building her new service. Is yours the same as ours - probably not? Do we need to loosen the oncology strings on SACT toxicity and encourage this to be a general medical issue. All this and more - Enjoy! | |||
| Episode 120: In the Clinic: Part 2 of the INTENSIFY trial with Professor Simon Crabb and Dr Sarah Chamberlain | 18 Sep 2026 | 00:22:21 | |
Welcome back to part 2 of our 2 part special on the INTENSIFY trail in metastatic prostate cancer study. We welcome back the wonder Professor Simon Crabb and Dr Sarah Chamberlain from the University Hospital Southampton where they work n the medical oncology department treating urological cancers. If you haven’t listened to part 1 please go check it out now where we set the foundations of the INTENSIFY trial. Now lets get in to the science behind the INTENSIFY study looking at eh DECIPHER score and pTEN. | |||
| Episode 119: In the Clinic - Discussing the INTENSIFY trial in metastatic prostate cancer with Professor Simon Crabb and Dr Sarah Chamberlain | 11 Sep 2026 | 00:21:49 | |
Welcome to the Simply Oncology Podcast. Today we are focusing in on the prostate cancer trial called INTENSIFY. This is a trial where we will look at intensifying metastatic prostate cancer patients. Those patients established on combination LHRHa and ARPi therapy could then be randomised at 6months to adding chemotherapy or not if they don't have an optimal PSA tumour marker improvement. We have brought the wonderful Professor Simon Crabb, and Dr Sarah Chamberlain from the oncology team at Southampton. They are part of the leadership team for the trial. This trial is already running in some centres and we discuss why it is happening and how it would be delivered. | |||
| Episode 118: Levelling the playing field in MIBC with Dr Mohini Varughese | 04 Sep 2026 | 00:20:39 | |
Welcome back to part 2 of this episode on radiotherapy in muscle invasive bladder cancer where we explore the challenging questions of equitable access to neoadjuvant and adjuvant novel therapies in patients not suitable for cystectomy. We welcome back the brilliant Dr Mohini Varughese, fighting the good fight for bladder preservation treatment! | |||
| Episode 117: Bladder cancer- Systemic therapy and Radiotherapy with Dr Mohini Varughese | 28 Aug 2026 | 00:27:40 | |
Welcome back! 🎙️We dive back in to the exciting and dynamic world of systemic therapy in localised muscle invasive bladder cancer 🔦Shining a spotlight on bladder preservation treatment ie: radiotherapy with a radiosensitiser, a key player in the curative treatment of this cancer. 🤷Is Radiotherapy at risk of being left behind with recent trials improving neoadjuvant and adjuvant systemic therapies with trials that have focussed exclusively on cystectomy. 🎙️We welcome back Dr Mohini Varughese from Royal Devon University Hospitals to take on this important topic in a 2 part episode! 🎙️What is the Real World Landscape like and how many people are having radiotherapy for muscle invasive bladder cancer?? All this and more! | |||
| Episode 116: Fundamentals - Nutrition in Cancer - Tackling the Myths with Chloe Nottingham, Dietitian | 21 Aug 2026 | 00:26:09 | |
🎙️Join us as we return with the excellent Chloe Nottingham to tackle some cancer diet myths. ❌Fasting ❌Alkali diets ❌No sugar diets 🥗Every year there is a new ‘Must Try’ diet to control your cancer. 🔎We look at the Social Media impact on what cancer patients are eating and the potential pitfalls of that. ‼️Nearly 40% of patients are following diet advice from social media that could be doing them harm!! 🤔Does a clever meme make you a good source of safe info??? 😫We also look at the ‘Feeding Pressure’ that some patients feel from loved ones who are trying their best to help. 🎙️Chloe talks so much sense we almost think it should be on another podcast!!! 👍Dietitians are an amazing resource to help support patients support themselves. 🥗Healthy eating 🍎alongside exercise 🏃♂️remain the best platform for a body to tackle cancer. 📢A must listen for anyone tackling cancer or their loved one. Enjoy and share!!! | |||
| Episode 115: Fundamentals - Nutrition in Cancer with Chloe Nottingham, Dietitian Part 1 | 14 Aug 2026 | 00:25:47 | |
We are what we eat. Join us as we discuss with the excellent Chloe Nottingham, a specialist cancer dietitian with years of experience.
Depending on the cancer type between 40-80% of patients suffer from malnutrition. Why is that so important; - Lower treatment tolerance - Lower treatment completion and doses - More delays getting onto treatment - Lower survival rates - Reduced wellbeing and energy - Longer hospital stays Getting good nutrition support and eating well can massively impact your cancer journey. Chloe helps us plan a route to healthy and sensible ways of keeping our body weight and muscles working. Enjoy!!! | |||
| Episode 114: Testosterone replacement therapy in Prostate cancer with Dr Samantha Strumeier | 07 Aug 2026 | 00:29:46 | |
Welcome back for our second of this 2 part special on testosterone in cancer with the excellent Dr Samantha Strumeier from Barts health NHS trust. Did you know that 10% of patients can end up with ongoing testosterone suppression after completing a course of androgen deprivation therapy. How do we tackle theses cases? What is the evidence. Sam marks john's strategy out of 10 with surprising results. | |||
| Episode 113: In the Clinic - Managing Low Testosterone in Cancer with Dr Samantha Strumeier | 31 Jul 2026 | 00:29:55 | |
Join us as we cover the effect of cancer and its treatment on Testosterone levels in cancer. We are joined by the amazing Samantha Strumeier, nurse consultant and nursing lead for urological cancers at St Barts Hospital London. Having experience in testosterone replacement therapy at Memorial Sloane Kettering Hospital New York she shares this with us and what she is doing now. We explore the impact of low testosterone in men on cancer treatment. One major area where this impacts the most is prostate cancer where we cause low testosterone with androgen deprivation therapy. What happens if testosterone stays low after the treatment finishes. We set the scene for how we can help patients with low testosterone. All this and Samantha tries not to be too disappointed by Mike and John!!! | |||
| Episode 112: Prostate Cancer, Exercise and lifestyle with Dr Lucy Gossage | 24 Jul 2026 | 00:26:46 | |
Lifestyle and patient choices in Prostate Cancer Prostate cancer has been part of a revolution in terms of treatment options and improved outcomes for our patients. How can we make that improvement in numbers on survival curves match the goals and needs of our patients? Join us in this second of 2 special live episodes of the Simply Oncology Podcast on Patient Choices and Lifestyle in Prostate Cancer. We talk to patient expert Tony Collier, Dr Lucy Gossage - an oncologist involved with Move Against Cancer and Professor Alison Birtle an oncologist with extensive experience treating prostate cancer. In this Episode we focus on Dr Lucy Gossage and her experience of supporting cancer. patients through exercise Lucy Gossage has a background in international level sport alongside being an oncologist, so it seemed natural for her to be involved in Move Against Cancer. We discuss the massive positive steps that giving patients permission to move and exercise can have for their health -both physical and mental. Recapturing some normality amongst the backdrop of cancer and its treatment can only be a good thing for patients. We hear about the huge positive impact that maintaining exercise has had on Tony’s life with cancer. We hope you enjoy! *This is a non-promotional podcast episode organised by Bayer PLC in partnership with Simply Oncology (Dr John McGrane and Dr Michael Rowe) to highlight the importance of holistic care in managing patients with prostate cancer. Bayer provided honoraria to the speakers of this podcast. The views and opinions expressed are those of the speakers and do not necessarily reflect those of Bayer PLC or Simply Oncology. This content is for educational purposes only and should not replace clinical judgement.* | |||
| Episode 111: Prostate Cancer through a patient Lens with Tony Collier BEM | 17 Jul 2026 | 00:34:55 | |
Lifestyle and patient choices in Prostate Cancer Prostate cancer has been part of a revolution in terms of treatment options and improved outcomes for our patients. How can we make that improvement in numbers on survival curves match the goals and needs of our patients? Join us in this first of 2 special live episodes of the Simply Oncology Podcast on Patient Choices and Lifestyle in Prostate Cancer. We talk to patient expert Tony Collier, Dr Lucy Gossage - an oncologist involved with Move Against Cancer and Professor Alison Birtle an oncologist with extensive experience treating prostate cancer. In this Episode we talk to Tony Collier about his experience of being a prostate cancer patient. We hear how the focus on treatment led him to have to advocate his quality of life and life goals himself. We hear how clinicians could align with patients’ goals with just a few simple questions. We hear about the huge positive impact that maintaining exercise has had on Tony’s life with cancer. Hearing Tony’s live experience of some very personal aspects of a cancer diagnosis and treatment is hugely moving and powerful. We hope you enjoy! *This is a non-promotional podcast episode organised by Bayer PLC in partnership with Simply Oncology (Dr John McGrane and Dr Michael Rowe) to highlight the importance of holistic care in managing patients with prostate cancer. Bayer provided honoraria to the speakers of this podcast. The views and opinions expressed are those of the speakers and do not necessarily reflect those of Bayer PLC or Simply Oncology. This content is for educational purposes only and should not replace clinical judgement.* | |||
| Episode 110: Part 2 of Managing Menopause in Gynaecological Cancers with Dr Shibani Nicum | 10 Jul 2026 | 00:21:09 | |
Join us as we finish our discussion on managing menopause in gynaecological cancers with the wonderful Shibani Nicum. Shibani works as as Associate Professor in Medical oncology treating gynaecological cancers at UCL Hospitals London. Shibani helped se up the meno.pause app in conjunction with the British Menopause Society to help guide clinical teams to support patients with menopause issues as part of their gynae cancer treatment. We look at setting up a complex menopause MDT and what lifestyle factors can help in this setting. As we see ongoing improvements in survival outcomes maintaining quality of life is so important and managing menopausal issue is a big part of that quality of life. Enjoy | |||
| Episode 109: In the Clinic - Managing Menopause in Gynae Cancers with Dr Shibani Nicum | 02 Jul 2026 | 00:23:16 | |
Menopause in Gynae Cancer patients is a major issue. If you struggle when to advise patients in this space. Join us as we discuss management of menopause in gynae cancer patients with excellent Dr Shibani Nicum from UCL hospitals London. Menopause across all cancer affects up to 60000 patients per year! In Gynae cancers such as ovarian cancer we can make someone menopausal immediately after surgery so that person is coping with menopause alongside surgery and chemotherapy side effects. Shibani has helped to develop the Meno.pause app to support healthcare teams with menopause treatment in cancer. It’s not just HRT - how best can we help support patients. - Oxybutynin - Neurokinin inhibitors - Lifestyle We discuss this and more Enjoy! | |||
| Episode 108: In the Clinic - The Revolution in Platinum resistant Ovarian Cancer with Dr Rowan Miller | 26 Jun 2026 | 00:31:28 | |
Join us for this special episode where we look at the recent major changes in the Platinum resistant ovarian cancer space . For so long this has been a treatment area with limited options and poor outcomes. Now we have ; - New Drugs - New targets - Better outcomes So much to discuss. We talk to the brilliant Dr Rowan Miller who specialises in gynaecological cancers and is based at UCL & St Barts Hospitals in London. Straight after her presentation on B7-H4 ADCs at the British Gynaecological Cancer Society meeting in Bristol we look at the new options and where they might sit in our treatment pathway? Will they all get funded? Can we manage the new side effects? Could they work in sequence or together?? A 'Must Listen' if you are involved in Ovarian Cancer. Enjoy | |||
| Episode 107: How do we explain risk to patients with Professor Mark Beresford | 17 Jun 2026 | 00:32:00 | |
Join us as we return with the wonderful Professor Mark Beresford from United Hospitals in Bath. We discuss how we as clinicians describe risk to our patients ans we look at some of the pitfalls of using relative risk, overcomplicated statistics with our patients. If we cannot explain risk to patients how can they ,make informed decisions. Mark moves into 'T-shirt Territory' by being our most frequent flyer on the podcast which earns him a coveted Simply Oncology Podcast T-Shirt. | |||
| Episode 106: In the Clinic - The Part 2 of the ADePT trial in Glioblastoma brain tumours with Dr Faye Robertson | 08 Jun 2026 | 00:19:14 | |
Join us as we return to our discussion on the fascinating ADePT trial in Glioblastoma brain tumours with the wonderful Dr Faye Robertson from the Western General Hospital, Edinburgh. We discuss how TGX-007 developed with TROGENIX with its super enhancers, dual payload and delivery system hopes to bring a break through in High grade Gliomas. We talk about how could this technology be 'rolled out' if successful. What level of success would be needed to develop the specialism for this kind of treatment. Could this therapy be adapted to be used in other cancer types such as pancreatic cancer etc ? With only 1 human trial patient clearly this is early days but we hope to follow this trial's progress on The Simply Oncology Podcast. Even if the survival outcomes of the trial were negative this trials move the dial in terms of what is possible from drug development and delivery. | |||
| Episode 105: In the Clinic - the ADePT Trial in Glioblastoma - dual payload gene therapy - with Dr Faye Robertson | 04 Jun 2026 | 00:24:18 | |
Sometimes we hear about a vision for a trial that is so novel and exciting that it takes you back a bit. This is one such moment. Join us as we talk to the amazing Dr Faye Robertson from the Edinburgh cancer Centre about the ingenious ADePT trial.
Led by Trogenix and the University of Edinburgh, it tests a breakthrough "Trojan horse" gene therapy designed to destroy cancer cells and stimulate the immune system. TGX-007 is a drug developed with Tregonix that: How it Works: It uses dual-payload technology to deliver two distinct therapeutic agents:
We have had many false dawns in GBM trials but we are very excited by the results so far with TGX-007.
| |||
| Episode 104: In the Clinic - Future directions in Pancreatic Cancer Radiotherapy with Dr Ganesh Radhakhrishna (part 2) | 29 May 2026 | 00:25:50 | |
We return to discuss the role of radiotherapy in the management of Pancreatic Cancer. What are the side effects of pancreatic radiotherapy and SABR? Do we need an MR Linac to deliver pancreatic SABR Where might pancreatic RT sit alongside new RAS inhibitor therapies? Enjoy | |||
| Episode 103: In the clinic - Radiotherapy in Pancreatic Cancer with Ganesh Radhakhrishna | 21 May 2026 | 00:30:48 | |
Today we are talking about the role of radiotherapy in Pancreatic Cancer with the superb Dr Ganesh Radhakrishna from the Christie Hospital in Manchester. Radiotherapy may play an increasing role in pancreatic cancer. Stereotactic ablative body radiotherapy (SABR) is helping to get excellent control rates in localised pancreatic cancer and may play a role alongside surgery in pancreatic cancer. Will radiotherapy ever replace surgery in select cases? | |||
| Episode 102: Fundamentals - Immunotherapy and Kidney Cancer: One Woman’s Story with Annie Anderson | 14 May 2026 | 00:30:35 | |
Join us as we talk to Annie Anderson to get a patient view on advanced kidney cancer and its treatment. Annie was diagnosed with stage IV Kidney Cancer in 2022 which had spread to liver, bone, brain. She went from climbing and running 18 miles to struggling to function. She describes the choices she made and how immunotherapy with has controlled her cancer and allowed her to continue her normal life. A really powerful thing to hear how Annie has tackled her diagnosis and aimed to take positive steps every day. She describes how continuing the things that give her joy like family, cold-water swimming and climbing have allowed her retain her sense of self along the way.
Enjoy | |||
| Episode 101: In the Clinic - The future of Adjuvant treatment in kidney cancer with Dr Will Ince and Dr Naveen Vasudev | 07 May 2026 | 00:28:03 | |
Join us as we complete our tour of the adjuvant kidney cancer treatment space. We are joined again by the excellent Dr Will Ince from Cambridge and Dr Naveen Vasudev from Leeds! In our last episode we discussed KEYNOTE 564 and the RAMPART study and where this places immunotherapy in adjuvant kidney cancer. In this episode we discuss the LITESPARK 022 trial and the addition of Belzutifan to Pembrolizumab in adjuvant kidney cancer treatment. We also discuss the potential for KIM-1 to be used as a biomarker to highlight those higher risk patients that may benefit from adjuvant immunotherapy. This is an exciting time for adjuvant treatment in kidney cancer. All this as Will continues to misbehave to amuse himself!! We hope you enjoy! | |||
| Episode 100: In the Clinic - Adjuvant Therapy in Kidney Cancer - The Treatment Landscape with Dr Will Ince and Dr Naveen Vasudev | 30 Apr 2026 | 00:36:36 | |
Joins us as we celebrate 100 episodes in style!! In the first of our 2 part special we tackle the Adjuvant Treatment Landscape in Kidney Cancer. We talk to Dr Will Ince from Addenbrookes Hospital Cambridge and Dr Naveen Vasudev from St James’s Hospital Leeds. We discuss the arrival of immunotherapy with the KEYNOTE 564 trial. We discuss the importance of the RAMPART study and backing up the concept of a survival signal from immunotherapy in adjuvant Kidney cancer. We discuss our concept of risk and benefit. Nav steers us through this evolving landscape whilst Will Ince generally misbehaves!!! Enjoy | |||
| Episode 99: Fundamentals- Early stage melanoma with Dr Toby Talbot (Part 2) | 24 Apr 2026 | 00:23:21 | |
Welcome back for Part 2 of our Early Melanoma series with Dr Toby Talbot. We dive in to the potential side effects of treatment and how this affects decisions about adjuvant treatment. We hear about adjuvant BRAF targeted therapy, with more side effects but temporary ones. We look at the future with the NADINA trial for neoadjuvant immunotherapy in high risk clinical stage III disease, the emerging role of cancer vaccines, and biomarkers to try and find the right treatment for the right patient. Tour de force as always. Keep an eye out for upcoming podcasts on the treatment of advanced/metastatic melanoma. | |||
| Episode 98: Fundamentals- Treating early stage melanoma with Dr Toby Talbot (Part 1) | 17 Apr 2026 | 00:23:53 | |
We welcome back our very own Dr Toby Talbot Consultant Clinical Oncologist at Royal Cornwall Hospital for his patient-focussed insights into managing early stage melanoma. In this two part series, we explore what melanoma is, why it comes about and how it is investigated. We discuss surgery, why this might be a two stage procedure and the importance of sentinel lymph node biopsy. We then delve into some of the drug treatments available, used to reduce the risk of the cancer coming back. We focus mainly on immunotherapy and the possible benefits of treatment in Part 1. Tune in next week for Part 2 where we explore some of the side effects of treatments, BRAF directed therapy and how these drugs are possibly going to be used before surgery. | |||
| Episode 97: Fundamentals - The Simply Oncology A to Z of oncology with Debbie Victor CNS | 09 Apr 2026 | 00:31:04 | |
Join us for something a bit different this week!! We though it would be fun ( and hopefully helpful) to make an A to Z of Oncology. Are you a patient or care who is newly diagnosed with cancer. Are you new to working around cancer care. Are you in training and want to learn more. Indeed- are you in cancer care and want to know why we have chosen our A to Z. We get the super experienced Clinical Nurse Specialist Debbie Victor to help us out. As Education trustee for the British Association of Urology Nurses she knows a thing or 2 about supporting patients in cancer. If you have a better A to Z please feel free to contact us and let us know!! If you want a recap the list is in the transcript👍 Enjoy | |||
| Episode 96: Artificial Intelligence in Radiotherapy - the ARCHERY trial with Professor Ajay Aggarwal | 25 Mar 2026 | 00:37:53 | |
Join us as we tackle the topic of Artificial intelligence in Radiotherapy. This week we speak to the excellent Professor Ajay Aggarwal about the use of AI in radiotherapy planning. We discuss the international ARCHERY trial using an AI radiotherapy planning tool to streamline radiotherapy planning in prostate, head & neck and cervical cancers. This PRA artificial planning tool developed at the MD Anderson hospital could unlock huge radiotherapy delivery potential in Low & middle income countries and beyond! This trial of 990 patients is being conducted in Jordan, South Africa, India and Malaysia. All radiotherapy trials are hard to get funded. This remains an area of need for oncology trial funding. Massive respect and congratulations to Ajay and the international team for getting unified treatment protocols and to actually prospectively test and AI solution in radiotherapy. We hope you enjoy Link below to the ARCHERY trial manuscript. https://bmjopen.bmj.com/content/13/12/e077253 | |||
| Episode 95: PSMA Lutetium in Prostate Cancer with Dr Amy Eccles -part 2 | 20 Mar 2026 | 00:23:06 | |
🎙️New Simply Oncology Podcast to complete our PSMA Lutetium in #ProstateCancer | |||
| Episode 94: PSMA Lutetium in Prostate Cancer with Dr Amy Eccles | 19 Mar 2026 | 00:29:06 | |
PSMA Lutetium has been in the background for metastatic prostate cancer for several years. Joins us as we discuss this exciting treatment in metastatic prostate cancer with the excellent Dr Amy Eccles who works at Imperial Hospital London and also the London Clinic. Amy is a radiologist who delivers PSMA Lutetium at the London Clinic and shares her experience with us. Attaching Lutetium-177 to PSMA to deliver a beta-emitting radiation payload to prostate cancer cells. Essentially targeted liquid radiotherapy. This is novel therapy that is not yet funded in the NHS. We discuss who a good patient may be and what potential side effects they could expect. This field of Theranostics is expending rapidly and where does this sit with our current prostate cancer treatment landscape?? | |||
| Episode 93: Fundamentals - Part 2 of Pelvic Radiation Disease with Lisa Durrant | 06 Mar 2026 | 00:24:36 | |
Late effects after pelvic radiotherapy part 2. Join us as we complete our conversation with the wonderful Macmillan Late effects consultant radiographer Lisa Durrant. Last week we discussed late bladder and bowel effects from radiotherapy. In this weeks episode we discuss; - hyperbaric oxygen therapy - pelvic floor exercises - pain as a late effect of radiotherapy - sexual function issues post radiotherapy Lisa gives us some great practical tips on how to support patients after their radiotherapy along the way. Enjoy! For more info on pelvic radiation disease and late effects from pelvic radiation check out www.prda.org.uk
| |||
| Episode 92: Fundamentals - Discussing Pelvic Radiation Disease with Lisa Durrant | 05 Mar 2026 | 00:24:26 | |
Join us as we discuss the impact of Pelvic Radiation Disease & the late effects of radiotherapy in the pelvis. We re always trying to get he best result for our patients and to cure cancer but we need to take time to deal with the impact of radiotherapy side effects in our patients. We are talking radiotherapy for pelvic cancers; bladder, prostate, gynaecological and rectal cancers. | |||
| Episode 91: In the Clinic - Biomarkers in advanced Kidney Cancer with Professor Laurence Albiges (part 2) | 26 Feb 2026 | 00:18:52 | |
Join us as return to our excellent conversation on biomarkers in kidney cancer with the wonderful Professor Laurence Albiges from Paris. 🎙️We finish our overview of Biomarkers in metastatic Kidney Cancer with the superb Professor Laurence Albiges from the Gustave Roussy Hospital in Paris 🇫🇷 | |||
| Episode 90: Biomarkers in Advanced Kidney Cancer with Professor Laurence Albiges (Part 1/2) | 19 Feb 2026 | 00:24:54 | |
Join us for a special Kidney Cancer treat!!! A Must Listen episode!! We discuss the role of biomarkers in advanced kidney cancer with the wonderful Professor Laurence Albiges from the Gustave Roussy Institute of Oncology in Paris. No Kidney Cancer talk is complete without the question -" Where are we with biomarkers?" This is part 1 of a 2 part walkthrough of the biomarker story so far in kidney cancer. Laurence is unequalled in her clear delivery on this subject. As lead for the CARE-1 study Laurence is examining the role of PDL1 as a biomarker in 1st line treatment of mRCC. We also discuss the; - IMDC criteria - Clusters - KIM-1 - PDL1 - Sarcomatoid features Recorded before Christmas this is a gift that keeps on giving. We hope you enjoy!! Check the Transcript for more details. | |||
| Episode 89: In the Clinic - Advanced Renal Cancer The Sequel: Professor Ricky Frazer Returns (part 2/2) | 05 Feb 2026 | 00:19:21 | |
Join us as we return to complete our run through the landscape of metastatic renal cancer with the effervescent Professor Ricky Frazer. We look at the Dolly Mixture of subtypes that makes up non clear cell renal carcinoma. We discuss the new HIF2a inhibitors such as belzutifan. We look at future directions in kidney cancer. A treat for anyone who treats kidney cancer. Enjoy! | |||
| Episode 88: In the clinic - Metastatic Renal Cancer with Professor Ricky Frazer (part 1/2) | 05 Feb 2026 | 00:27:38 | |
Join us is as we celebrate Kidney Cancer week with a Masterclass walk through metastatic Renal Cancer with Professor Ricky Frazer from Velindre Cancer Centre. Ricky is a co-host of the hugely successful Immunobuddies podcast and has a vast experience in immunotherapy management. We look at the indications for immunotherapy versus anti-VEGF TKI therapy. Should we just accept anti-VEGF TKI monotherapy in Favourable Risk patients? When should we try IO/IO combination versus IO/TKI combinations in the first line setting? All this whilst Ricky looks to put John in his place!! Enjoy | |||
| Episode 87: The Landscape for Metastatic Endometrial Cancer with Dr Gemma Eminowicz (Part 2/2) | 29 Jan 2026 | 00:30:07 | |
Join us for Part 2 of our Metastatic Endometrial Cancer special with the amazing Dr Gemma Eminowicz from University College London Hospital. In episode 1 we looked at molecular profiling and immunotherapy. In this episode we explore the role of; - hormone therapy - Antibody drug conjugates - PARP inhibitors Endometrial cancer is taking off in terms of new and exciting treatment options. Gemma does an amazing job talking us through them. Enjoy. | |||
| Episode 86: The Metastatic Endometrial Cancer landscape with Dr Gemma Eminowicz (1/2) | 22 Jan 2026 | 00:22:08 | |
Dr Gemma Eminowicz returns for 2026!! Join us as we discuss the metastatic endometrial cancer landscape with Simply Oncology 'friend of the show' Dr Gemma Eminowicz from University College Hospital London. Advanced endometrial cancer is so much more than carboplatin and paclitaxel. It now has the complete range of oncological treatments; - Chemotherapy - Immunotherapy - Antibody Drug Conjugates - Hormone therapy - Targeted therapy - Radiotherapy We look at how the molecular testing in endometrial cancer has shaped advanced endometrial cancer therapy. We look at the arrival of chemo-immunotherapy in the MMRd group and now in the MMRp patient group. In the MMR proficient group we discuss the merits of 1st line Chemo-immunotherapy versus sequencing treatment to allow potential VEGF targeted therapy. Gemma shares her invaluable experience and helps Mike understand advanced endometrial cancer. Enjoy!! | |||
| Episode 85: Future directions in advanced Oesophago-Gastric cancer with Dr Lizzy Smyth | 13 Jan 2026 | 00:20:08 | |
We return for part 2 of our overview on metastatic oesphago-gastric cancer. Join us as we welcome back Dr Lizzy Smyth from Oxford University Hospitals. We look at the importance of nutritional support. We discuss future directions such as CAR-T therapy Lizzy mocks John (again!!) A brilliant finish to our OG masterclass from Lizzy. Enjoy! | |||
| Episode 84; In the Clinic - Discussing metastatic Oesophago-Gastric Cancer with Dr Lizzie Smyth | 05 Jan 2026 | 00:25:27 | |
Dr Lizzie Smyth from Oxford University Hospitals gives us a an amazing 2 part overview of management of metastatic Oesophago-Gastric cancer. We discuss molecular testing and therapy options in metastatic OG cancer🧬 Enjoy! | |||
| Episode 82: in the Clinic - PARP inhibitors in metastatic Prostate Cancer with Professor Rob Jones | 24 Dec 2025 | 00:27:57 | |
Join us as we unwind in the Christmas Holiday period with a masterful overview of PARP inhibitors in metastatic prostate cancer with Professor Rob Jones. Rob is an old friend of the show and is amazing at setting the scene for who & when PARP inhibitors can be useful in metastatic prostate cancer. | |||
| Episode 83: In the Clinic - Part 2 of PARPi in prostate cancer with Professor Rob Jones | 24 Dec 2025 | 00:21:53 | |
Happy New Year!!! WE return in 2026 to complete our overview of PARPi in prostate cancer with the peerless Professor Rob Jones. | |||
| Episode 81: Part 2 Management of menopause and breast cancer with Dr Rebecca Bowen | 19 Dec 2025 | 00:21:00 | |
Welcome back! In part 1 we discussed the major effects of menopause and how these can be worsened by hormonal medications given to treat breast cancer and the impact these can have on patients completing treatment as planned. In this episode we welcome back Dr Rebecca Bowen and discuss practical advice on managing these symptoms including a link to what will be a vital resource for all clinicians in Oncology and Primary Care: the Meno.Pause app. Link below, download today! Meno.Pause App We wish all our wonderful listeners and guests a very Merry Christmas, thank you as always for tuning in, John and Mike. | |||
| Episode 80: Part 1 Menopause management and breast cancer with Dr Rebecca Bowen | 12 Dec 2025 | 00:22:57 | |
When is it safe to giving HRT in women who are being treated or have previously been diagnosed with breast cancer? Will the use of vaginal oestrogens affect breast cancer outcomes? What is the trade off on quality of life when symptoms of the menopause aren't managed? Did you know that roughly 1 in 4 women stop their hormone therapy for breast cancer due to menopausal side effects!! Who better to answer these questions and more than Dr Rebecca Bowen, Consultant Oncologist in Royal University Hospitals Bath who specialises in the treatment of breast and gynaecological cancers and heads up the specialist cancer and menopause unit. | |||
| Episode 79 - Fundamentals: Discussing sexual health in cancer with Lorraine Grover | 02 Dec 2025 | 00:40:48 | |
Sexual health in cancer is a topic we need to talk more about. So many patients feel unable to discuss their sexual health and also clinical teams don’t also mange to bring the topic up. A cancer diagnosis can affect self image and confidence. We talk to Lorraine Grover who is a sexual health specialist nurse about how we can break down some of these barriers. Erectile dysfunction and much more discussed. You may never look at a Calypo ice lolly the same again !! This episode does contain some adult themes. | |||
| Episode 78 - In the Clinic: Discussing molecular profiles in metastatic bowel cancer with Professor Naureen Starling (part2) | 27 Nov 2025 | 00:26:12 | |
We return to Part 2 of our walk through metastatic bowel cancer with the excellent Professor Naureen Starling. We look at RAS, BRAF and future directions for treatment of metastatic bowel cancer. Can ctDNA have a role in metastatic bowel cancer? What role may HER2 have to play going forward? What is exciting on the horizon in mCRC? Enjoy!! | |||
| Episode 77: In the Clinic with Professor Naureen Starling discussing metastatic colorectal cancer (part 1) | 20 Nov 2025 | 00:31:56 | |
| Episode 76: Part 2 Discussing Cancer Care in the Transgender Community with Dr Alison Berner | 13 Nov 2025 | 00:24:25 | |
Join us as we return for Part 2 with the superb Dr Alison Berner. It’s Transgender Awareness Week and we discuss resources to support patients and clinicians. We discuss OUTpatients and UCATS - UK cancer and transition service. | |||